Sensiks — Visionary Executive Summary

SENSIKS — Executive Summary (PDF)

Embedded viewer with controls. Best viewed fullscreen on desktop.

Open PDF in new tab · Download PDF

SENSIKS: PIONEERING SENSORY REALITY FOR MENTAL HEALTH & WELLBEING

Executive Summary – Updated October 2025

The Opportunity

The global mental health crisis—affecting 1B+ people with burnout, depression, anxiety, PTSD, addictions, and chronic stress—costs $1T+ annually (WHO), intensified by post-COVID challenges, geopolitical instability, and societal pressures. In the U.S., 1 in 5 adults experiences mental illness, with 55–70% untreated due to barriers including stigma, cost, and access (NIMH, 2025).

Current solutions fall short: Pharmaceuticals offer symptomatic relief but carry side effects and 30–50% relapse rates; CBT and talk therapy are slow and costly with limited limbic access; digital apps and audiovisual VR achieve modest effect sizes (d=0.5–0.7); wearables measure but don't intervene. These fragmented, cognitive-chemical approaches leave a 70% unmet need for rapid, accessible, side-effect-free emotional regulation tools (APA).

The Solution: Sensory Reality

Sensiks addresses this gap with Sensory Reality (SR), the world's first full-stack closed-loop platform for multisensory integration (MSI) since 2011. Developed with TNO/Delft University and government grants, SR transforms audiovisual VR, digital health, and CBT into full-spectrum experiences through bio-adaptive Pods.

Platform Architecture

Hardware: Bio-Adaptive Pods

• Visual: 1,800–6,500K CCT LED arrays for circadian spectrum control
• Audio: Immersive 7.1 spatial soundscapes with sub-50ms latency
• Olfactory: IFRA-aligned programmable scent cartridges
• Haptic: 20–120 Hz vibration with 40Hz gamma mode
• Thermal: Warm/cool gradient generation via IR heating
• Airflow: 0.0–0.8 m/s directional patterns
• Sensors: Continuous HRV, GSR, respiration, motion tracking, optional EEG

Software & AI: StateShifter Intelligence

• Real-time biofeedback fusion from multiple sources (HRV, GSR, EEG)
• Affective state modeling (arousal, valence, cognitive load)
• Sub-second latency from sensor to actuation
• Personalized response models (4x faster target-state by session 10)
• Content library with therapeutic protocols and SDK/API

Validated Science

Independent Research (2021-2025)

80-90% of peer-reviewed studies confirm MSI enhances therapeutic outcomes by 20–50% over single-modality interventions (Cohen's d ≈ 0.6–0.8). Key findings from investigator-initiated studies:

• Kindt & Soeter (2023, Frontiers in Psychiatry): Veterans PTSD study using Sensiks for multisensory memory reactivation + imagery rescripting + propranolol showed 4/7 participants with 30-40 point PCL-5 reductions; 5/7 showed QoL improvements
• de Jesus (2025, INRS-EMT): Ultra-Reality (multisensory) showed deeper relaxation vs standard AV-VR (p<.01); positive effects lasting 3 months in responders; EEG neuromarkers predict improvement by session 3
• Vermetten et al. (2021, Frontiers in VR): Personalized multisensory cues intensified emotional recall and engagement in veterans; proper congruency and monitoring maintains therapeutic window of tolerance
• Lopes & Falk (2024, Frontiers in VR): Systematic review showed positive impact from adding olfactory components; outcomes comparable to real nature exposure

Mechanisms Validated:

• Multisensory Integration: Engages insula, amygdala, hippocampus, prefrontal cortex for enhanced presence and emotional salience
• Autonomic Regulation: HRV improvements of 20-30%, indicating vagal activation and HPA-axis downregulation
• Psychoneuroimmunology: Cortisol reduction 15-40%, supporting immune balance
• Neuroplastic Pathways: Memory reconsolidation and adaptive emotional relearning

Applications

Preventive Wellbeing (€750/mo tier)

• 10-20 minute sessions for stress recovery and resilience
• Corporate wellness, healthcare settings, care homes
• Objective metrics (HRV, GSR) for program validation

Therapeutic Adjunct (€1,500-2,500/month tier)

• Enhances CBT, VRET, EMDR with embodied regulation
• Clinician-controlled protocols with real-time biofeedback
• GDPR/HIPAA compliant; pathway to MDR/FDA clearance

Research Platform (€1,200-2,000/month tier)

• Programmable APIs for custom protocols
• Multi-modal data capture (HRV, EEG, GSR, motion)
• Academic and commercial R&D applications

Proven Deployment

• 60+ MVP installations since 2017 (8+ years robust operation)
• Prestigious clients: NHS, UK Ministry of Defence, ARQ National Psychotrauma Centre, universities, KLM, Givaudan, Mars, Barclays, PwC, Tony Robbins
• 25,000+ legacy cabinets deployed since 2005
• Independent peer-reviewed research from LUMC, ARQ, TNO, INRS-EMT

V2 ROADMAP (Q1 2026 Launch)

• Scalable modular hardware architecture
• Expanded SDK with AI-generated content tools
• Enhanced real-time adaptive dosing algorithms
• Pathway to wellness device certification
• Optional medical device classification for therapeutic claims

Market Opportunity

Positioned at intersection of high-growth sectors:

• Corporate Wellness: $68.02B (2024) → $130.03B (2034)
• Behavioral Health: $184.94B (2024) → $330.35B (2034)
• VR/AR Healthcare: $1.9B (2024) → $2.4B (2025), +26% YoY (fastest growth)
• Mental Health Tech: $1.94B (2024) → $5.6B (2025), +16% YoY
• Digital Therapeutics: $3.2B (2024) → $3.8B (2025), +19% YoY

Total Addressable Market (TAM): $785B+

Serviceable Obtainable Market (SOM):

• Near-term: €200–500M
• By 2030: €1B+

Competitive Advantage

Investment trends favor Sensiks positioning:

• ✓ B2B enterprise model (vs. challenged D2C apps)
• ✓ Hardware + software moat (premium valuations)
• ✓ Clinical validation (peer-reviewed research)
• ✓ AI integration (37% of 2024 digital health funding)
• ✓ Multi-stream revenue (HaaS + SaaS + content licensing)

Differentiation: Only platform offering full 5+ sense integration with AI orchestration and biofeedback, vs. competitors limited to visual-audio VR (AppliedVR $71M, XRHealth $40M, Limbix $38.5M, Tripp $28.2M).

Business Model

Hybrid recurring revenue:

• Hardware-as-a-Service: 35–55% gross margins
• SaaS subscriptions: 85–90% gross margins
• Content marketplace: 70–85% gross margins

Tiered Pricing:

• Preventive Wellbeing: €750/mo
• Clinical/Therapeutic: €1,500–2,500/month
• Research Platform: €1,200–2,000/month

Financial Projections:

• 2029 Revenue: €82M
• Recurring Revenue: 45%
• Path to 350-850 deployed units within 3 years

Investment Opportunity

Seeking: €8M Series A at €35M post-money valuation (tranched)

Use of Funds:

• V2 production and scaling
• Randomized controlled trials (RCTs)
• Regulatory pathways (MDR/FDA)
• Market expansion (EU, US, Canada)
• Sales and clinical team expansion

Exit Potential:

3–5x returns through:

• Strategic acquisition (digital health platforms, pharma, wellness providers)
• IPO in high-growth AI-neurotech sector
• Recent comparables: BehaVR acquired by XRHealth, Limbix by Big Health

Market Timing: Optimal window before major consolidation; VR/AR healthcare growing fastest (26% YoY); hardware-enabled platforms commanding 4-8x ARR valuations.

The Paradigm Shift

Sensiks bridges cognitive and embodied health as a new category—"Sensory Reality"—enhancing resilience, quality of life, and emotional processing without side effects. By uniting multisensory neuroscience, affective AI, and bio-adaptive hardware, we deliver measurable pathways for stress regulation and therapeutic enhancement, creating scalable infrastructure for the future of embodied digital health.

From therapy rooms to everyday environments, Sensiks provides the missing link: a scientifically-validated, hardware-enabled platform that makes emotional regulation accessible, effective, and side-effect-free /